Journal of Antimicrobial Chemotherapy (2000) 45, 41-47
© 2000 The British Society for Antimicrobial Chemotherapy
Macrolide resistance in group A streptococci
a Department of Clinical and Biological Sciences, University of Torino; b Laboratory, Agnelli Hospital, Pinerolo (Torino); c Laboratory, Paediatric Hospital, Torino, Italy
Two hundred and twenty one Streptococcus pyogenes isolates collected from throat swabs of untreated children with uncomplicated pharyngotonsillitis living in two centres situated in the north of Italy were tested to evaluate their macrolide resistance phenotype. Isolates were also typed for T protein and assayed for opacity factor (OF) and protease production. Resistance to macrolides was found to be similar in the two centres. Fifty-one point two per cent of Torino strains and 43.5% of Pinerolo strains were not inhibited by erythromycin. Resistant strains belonged to one of three phenotypes: CR, constitutive resistance (37.9 and 42.5% in Torino and Pinerolo, respectively); IR, inducible resistance (40.9 and 17.5%); NR, new resistance phenotype (21.2 and 40%). All the resistant and some of the susceptible strains were analysed by pulsed-field gel electrophoresis and genomic patterns were defined on the basis of band size and number. Five DNA profiles were found among erythromycin-resistant strains: three patterns characterized the NR resistance phenotype and one each the IR and CR phenotypes. The distribution of resistant strains according to their genomic patterns appears to be related to the resistance phenotype and only in some cases to the T serotype of bacteria. We conclude that the S. pyogenes strains analysed are genetically heterogeneous and therefore the high rate of erythromycin resistance observed is not caused by the spread of a single clone nor is it related to a particular serotype.
* Correspondence address. Department of Clinical and Biological Sciences, University of Torino, S. Luigi Hospital, Regione Gonzole 10, 10043 Orbassano (Torino), Italy. Tel: +39-0116708127; Fax: +39-0119038639; E-mail: savoia{at}pasteur.sluigi.unito.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. A. Figueiredo, S. I. Aguiar, J. Melo-Cristino, and M. Ramirez DNA Methylase Activity as a Marker for the Presence of a Family of Phage-Like Elements Conferring Efflux-Mediated Macrolide Resistance in Streptococci Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3689 - 3694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Baltch, L. H. Bopp, R. P. Smith, P. B. Michelsen, and W. J. Ritz Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes J. Antimicrob. Chemother., July 1, 2005; 56(1): 104 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Smith, A. L. Baltch, P. B. Michelsen, W. J. Ritz, and R. Alteri Use of the Microbial Growth Curve in Postantibiotic Effect Studies of Legionella pneumophila Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sauermann, R. Gattringer, W. Graninger, A. Buxbaum, and A. Georgopoulos Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics J. Antimicrob. Chemother., January 1, 2003; 51(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dicuonzo, E. Fiscarelli, G. Gherardi, G. Lorino, F. Battistoni, S. Landi, M. De Cesaris, T. Petitti, and B. Beall Erythromycin-Resistant Pharyngeal Isolates of Streptococcus pyogenes Recovered in Italy Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3987 - 3990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagai, P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, et al. Susceptibility to Telithromycin in 1,011 Streptococcus pyogenes Isolates from 10 Central and Eastern European Countries Antimicrob. Agents Chemother., February 1, 2002; 46(2): 546 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagai, T. A. Davies, L. M. Ednie, A. Bryskier, E. Palavecino, M. R. Jacobs, and P. C. Appelbaum Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenes Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3242 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Weber, J. Filipecki, E. Bingen, F. Fitoussi, G. Goldfarb, J. P. Chauvin, C. Reitz, and H. Portier Genetic and phenotypic characterization of macrolide resistance in group A streptococci isolated from adults with pharyngo-tonsillitis in France J. Antimicrob. Chemother., August 1, 2001; 48(2): 291 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Edelstein, T. Shinzato, E. Doyle, and M. A. C. Edelstein In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2204 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kleinkauf, G. Ackermann, R. Schaumann, and A. C. Rodloff Comparative In Vitro Activities of Gemifloxacin, Other Quinolones, and Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1896 - 1899. [Abstract] [Full Text]
|
|